NASDAQ:IBIO iBio Q1 2025 Earnings Report $1.43 0.00 (0.00%) As of 08/21/2026 04:00 PM Eastern ProfileEarnings HistoryForecast iBio EPS ResultsActual EPS-$0.46Consensus EPS -$0.46Beat/MissMet ExpectationsOne Year Ago EPSN/AiBio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AiBio Announcement DetailsQuarterQ1 2025Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time4:00PM ETUpcoming EarningsiBio's Q4 2026 earnings is estimated for Friday, September 4, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) iBio Earnings HeadlinesiBio (NASDAQ:IBIO) Rating Lowered to "Sell" at Wall Street ZenAugust 23 at 1:13 AM | americanbankingnews.comiBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to "Hold" RatingAugust 15, 2026 | americanbankingnews.comSilicon Valley Insider: "Forget AI Stocks"A 25-year Silicon Valley veteran who recommended Nvidia before its 32,000 percent run says the next wave of AI gains wont come from Nvidia, Tesla, or SpaceX. He points to a detail buried on page 37 of the SpaceX IPO filing, tied to Elon Musks plans for 1 million AI satellites, 1 billion humanoid robots, and 200 billion AI chips a year. He says one overlooked sector could benefit most from this spending, and has identified a company trading under $1 that may factor into Musks supply chain. | Brownstone Research (Ad)iBio Names Dr. Molly Carr as Chief Medical Officer to Advance Clinical-Stage PipelineAugust 4, 2026 | quiverquant.comQiBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical OfficerAugust 4, 2026 | globenewswire.comiBio Updates Governance Deadlines for 2026 Annual MeetingJuly 17, 2026 | tipranks.comSee More iBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email. Email Address About iBioiBio (NASDAQ:IBIO), a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.View iBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/17 - 08/21Flash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to Watch$27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t OverRoss Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx Miss3 Stocks Came Roaring Back—Now They’re Flashing Warning SignsMicrosoft's Sell-Off May Be a Gift, Not a WarningIs Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? Upcoming Earnings Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
